Rifampin plus Pyrazinamide for Treatment of Latent Tuberculosis Infection (LTBI)

August 12, 2003

Audience: Infectious Disease and other healthcare professionals

The Centers for Disease Control and Prevention (CDC) notified healthcare professionals of revised recommendations against the use of rifampin plus pyrazinamide for treatment of latent tuberculosis infection, due to high rates of hospitalization and death from liver injury associated with the combined use of these drugs.

[August 8, 2003 Letter - CDC]
[August 8, 2003 MMWR Article - CDC]

View comments

Hide
(web1)